Initial reaction to branded generics proposals is positive
Initial reaction to the proposals on changes to the way in which branded
generic medicines are reimbursed has been positive.
Martin Sawer, executive director of the British Association of Pharmaceutical
Wholesalers, commented: “Moving branded generics out of the Pharmaceutical
Price Regulation Scheme seems to make sense — the PPRS is about
setting prices for companies who need to be rewarded for the investment
they make in research and development of new products. Including branded
generics clouds the agreement.”
A spokesman for the British Generic Manufacturers Association said: “The
BGMA believes that all products sold in the off-patent market should
be covered by the new generics pricing scheme — this should include
the original brand.” He added: “We do not feel there is any
justification for the original brand to be dealt with in a different
way to generics once a product’s patent has expired.”
Sue Sharpe, the Pharmaceutical Services Negotiating Committee’s
chief executive, said that the PSNC is considering its response. “The
new contract funding arrangements will include reduction in reimbursement
prices for many generic medicines, and we expect this to have a significant
impact on branded generic prescribing,” she commented. |
The
Pharmaceutical Journal
Acrobat
Reader